ArticleScientific reports2018
Diffusion weighted MRI as an early predictor of tumor response to hypofractionated stereotactic boost for prostate cancer.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Restriction-Weighted Q-Space Trajectory Imaging (ResQ): Toward Mapping Diffusion-Time Effects With Tensor-Valued Diffusion Encoding in Human Prostate Cancer Xenografts.NMR in biomedicine · 2026Article
- MRI-Derived Biomarkers and Radiomic Signatures for Early, Dose-Dependent Evaluation of Prostate Cancer Radiotherapy: An Exploratory Study.Journal of imaging · 2026Article
- Anatomical zone and tissue type impacts the repeatability of quantitative MRI parameters and radiomic features for longitudinal monitoring of treatment response in the prostate.Magma (New York, N.Y.) · 2025Article
- Repeatability and reproducibility of prostate apparent diffusion coefficient values on a 1.5 T magnetic resonance linear accelerator.Physics and imaging in radiation oncology · 2024Article
- Early change in apparent diffusion coefficient as a predictor of response to neoadjuvant androgen deprivation and external beam radiation therapy for intermediate- to high-risk prostate cancer.Clinical radiology · 2024Article
- Article
- The role of MRI in prostate cancer: current and future directions.Magma (New York, N.Y.) · 2022Review
- A prospective study assessing the pattern of response of local disease at DCE-MRI after salvage radiotherapy for prostate cancer.Clinical and translational radiation oncology · 2022Article
- Adaptive magnetic resonance image guided radiation for intact localized prostate cancer how to optimally test a rapidly emerging technology.Frontiers in oncology · 2022Review
- Feasibility of a multiparametric MRI protocol for imaging biomarkers associated with neoadjuvant radiotherapy for soft tissue sarcoma.BJR open · 2021Article
- A review of the role of MRI in diagnosis and treatment of early stage lung cancer.Clinical and translational radiation oncology · 2020Review
- Conceptual review of key themes in treating prostate cancer in older adults.Journal of geriatric oncology · 2020Review
- Basic concepts and applications of functional magnetic resonance imaging for radiotherapy of prostate cancer.Physics and imaging in radiation oncology · 2019Review
- Multimodal imaging for radiation therapy planning in patients with primary prostate cancer.Physics and imaging in radiation oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
We evaluated the feasibility of using the kinetic of diffusion-weighted MRI (DWI) and the normalized apparent coefficient diffusion (ADC) map value as an early biomarker in patients treated by external beam radiotherapy (EBRT). Twelve patients were included within the frame of a multicenter phase II trial and treated for intermediate risk prostate cancer (PCa). Multiparametric MRI was performed before treatment (M0) and every 6 months until M24. Association between nADC and PSA or PSA kinetic was evaluated using the test of nullity of the Spearman correlation coefficient. The median rates of PSA at the time of diagnosis, two years and four years after EBRT were 9.29 ng/ml (range from 5.26 to 17.67), 0.68 ng/ml (0.07-2.7), 0.47 ng/ml (0.09-1.39), respectively. Median nADC increased from 1.14 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.